diff --git a/.last-update.json b/.last-update.json index 2f90462..1f0fa86 100644 --- a/.last-update.json +++ b/.last-update.json @@ -1,5 +1,5 @@ { - "updatedAt": "2026-07-29T18:13:32.946Z", + "updatedAt": "2026-07-30T18:21:11.269Z", "command": "update", "model": "MiniMax-M3" } diff --git a/commitments.md b/commitments.md index 60c9119..853e9cc 100644 --- a/commitments.md +++ b/commitments.md @@ -39,6 +39,20 @@ Concrete work tasks, follow-ups, approvals, and scheduled items extracted from G - Status: open - Notes: Material new development in the China regulatory lane — sits **on top of** the existing `china-cde-cell-gene-therapy-rules-2026` and `china-order-no-818-clinical-translation` items, not replacing them. Two positive signals (Merck–Bio-Techne acquisition; CARsgen satri-cel solid-tumor CAR-T approval) show the China CGT manufacturing environment is consolidating around advanced therapeutics. One negative signal (gene-editing trial death + published regulatory backlash) could foreshadow stricter CDE / NMPA / hospital-level oversight and tighter qualification criteria for "qualified hospitals" under Order No. 818. Together these affect: (a) qualification timelines for the CellShot-TriArm and ClinoReactor-class deals Robin has in flight, (b) which "qualified hospitals" remain eligible to host first-in-human studies, (c) whether CelVivo / 3Brain / Cellink vendor positioning for Chinese pharma R&D / CDMO accounts needs to change tone (e.g. emphasize safety documentation, IRB-grade workflows). Pull NMPA / hospital-IRB statements on the gene-editing trial case before next Chinese customer conversation. +### 3brain-coreplate-2026-conference-positioning: verify current CorePlate campaign and retrieve application material on next 3Brain check +- Owner: me +- Source: web-search — 3Brain official website plus 3Brain organization material captured through LinkedIn in Tavily pull 7 (2026-07-30); the dated result is 2026-07-25 and names ISSCR 2026 booth 412, while the company page also names ELRIG Drug Discovery booth 4 +- Due: unscheduled +- Status: open +- Notes: First credible direct 3Brain evidence after five Tavily pulls dominated by an unrelated EEG-paper mis-attribution. Vendor material positions CorePlate-enabled HD-MEA for high-resolution, scalable functional readouts from iPSC neuronal/cardiac models, brain organoids, assembloids, and 3D spheroids. Confirm which conference posts are current, obtain the named posters/application notes, and map them to Chinese neural-organoid and pharma-screening prospects. This pull does not establish CorePlate 1W/6W load force or Sample Holder Set details. + +### celvivo-clinostar-2-nams-demo-2026: verify product naming and campaign provenance on next CelVivo check +- Owner: me +- Source: web-search — Instagram snippets surfaced in Tavily pull 7 (2026-07-30): ClinoStar webinar copy (`DbaUZjIjMgK`), NexUs Locus on-site demo copy dated 2026-07-24 (`DbKYC4NBtrN`), and ClinoStar 2 NAMs positioning (`DbSl7nkoFjK`) +- Due: unscheduled +- Status: open +- Notes: Watchlist lead, not a confirmed launch or customer win. Verify that the posts come from CelVivo or an authorized distributor, whether `ClinoStar 2` is current official product naming, and whether the NexUs Locus live demo produced reusable data or contacts. The result set does not support Tavily's “installed base” language; one malformed duplicate URL was discarded. +